Zentalis Pharmaceuticals, Inc.

US$1.72As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:ZNTLHealthcare
Country USA
PE (Fwd) •••
TSR 7Y CAGR (37.01%)
Div yield —
ROE (66.75%)
Biotechnology
Beta (5Y) 1.93
PE TTM —
TSR TTM 14.67%
Mkt cap US$162.8M
ROIC (37.81%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$2.17
26.40%
(74.72%)
Hold 7|7|11|11|9
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.02
0.02
0.02
0.02
27.73%
14.96%
8.14%
14.64%
Revenue$M
10.89
10.82
10.66
10.37
6.43%
7.65%
2.80%
(4.56%)
Peers (US$162.8M)
Cap (US$)
PE
161.1M
—
Capital
TTM
5Y
10Y
Leveragex
0.680
0.191
0.202
EBIT/Intx
0.359
0.179
0.179
Own earn%
20.60
168.79
138.46
Sh yield%
15.63
44.00
43.48
Owners
Insiders/Inst%
1.09
63.02
Short interest%
2.59
SBC / revenue%
5.18
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
22
Op margin range%
14–18
$1 testx
0.0
Incr. ROIC%
6